Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study

Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study

Abstract Background Chronic obstructive pulmonary disease (COPD) is a progressive disease and a composite endpoint could be an indicator of treatment effect on disease worsening. This post-hoc analysis assessed whether indacaterol/glycopyrronium (IND/GLY) 110/50 μg once daily reduced the risk of cli...

Full description

Bibliographic Details
Main Authors: Antonio R. Anzueto, Konstantinos Kostikas, Karen Mezzi, Steven Shen, Michael Larbig, Francesco Patalano, Robert Fogel, Donald Banerji, Jadwiga A. Wedzicha
Format: Article
Language:English
Published: BMC 2018-06-01
Series:Respiratory Research
Subjects:
Chronic obstructive pulmonary disease
COPD
Clinically important deterioration
CID
Indacaterol/glycopyrronium
Salmeterol/fluticasone
Online Access:http://link.springer.com/article/10.1186/s12931-018-0830-z

Internet

http://link.springer.com/article/10.1186/s12931-018-0830-z

Similar Items